Scottish Liver Transplant Unit, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK.
Transpl Int. 2019 Aug;32(8):808-819. doi: 10.1111/tri.13416. Epub 2019 Mar 20.
It is unclear whether liver transplantation confers an increase in health-related quality of life (HR-QoL) across all dimensions of health. This study aimed to estimate the effect of liver transplantation on HR-QoL. Pre- and post-transplantation patients attending an outpatient clinic were invited to complete the condition-specific 'Short form of liver disease QOL' questionnaire. Mixed-effect linear regression and propensity-score matching (PSM) on pretransplantation characteristics were used to estimate the difference in overall HR-QoL associated with transplantation. Of 454/609 (74.5%) eligible patients who were included in the analysis, 102 (22.5%) patients fall under pretransplantation category, and 352 (77.5%) were under post-transplantation category. Overall HR-QoL post-transplantation significantly increased in patients without hepatocellular carcinoma (HCC) (β = 16.84, 95% CI: 13.33 to 20.35, P < 0.001), but not with HCC (β = 1.25, 95% CI: -5.09 to 7.60, P = 0.704). Donation after circulatory death (DCD) organ recipients had a significantly lower HR-QoL (β = -4.61, 95% CI: -8.95 to -0.24, P = 0.043). Following PSM, transplantation was associated with a significant increase in overall HR-QoL (average treatment effect: 6.3, 95% CI: 2.1-10.9). There is a significant improvement in HR-QoL attributable to transplantation in this cohort. Post-transplantation HR-QoL was affected by several factors, including HCC status and DCD transplantation, which has important implications for counselling prior to liver transplantation.
目前尚不清楚肝移植是否会在所有健康维度上提高健康相关生活质量(HR-QoL)。本研究旨在评估肝移植对 HR-QoL 的影响。邀请在门诊就诊的移植前和移植后患者完成特定于疾病的“肝病 QOL 简短问卷”。使用混合效应线性回归和移植前特征的倾向评分匹配(PSM)来估计与移植相关的总体 HR-QoL 的差异。在纳入分析的 609 名符合条件的患者中,有 454 名(74.5%)患者,102 名(22.5%)患者属于移植前类别,352 名(77.5%)患者属于移植后类别。无肝细胞癌(HCC)患者移植后总体 HR-QoL 显著提高(β=16.84,95%CI:13.33 至 20.35,P<0.001),但 HCC 患者则不然(β=1.25,95%CI:-5.09 至 7.60,P=0.704)。接受心脏死亡后供体(DCD)器官移植的患者 HR-QoL 显著降低(β=-4.61,95%CI:-8.95 至-0.24,P=0.043)。经过 PSM 后,移植与总体 HR-QoL 的显著提高相关(平均治疗效果:6.3,95%CI:2.1-10.9)。在该队列中,移植后 HR-QoL 有显著改善。移植后 HR-QoL 受到多种因素的影响,包括 HCC 状态和 DCD 移植,这对肝移植前咨询具有重要意义。